New study digs into long-term survival data for advanced lung cancer patients on immunotherapy

NCT ID NCT07478809

Recruiting now Knowledge-focused Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks back at patients with advanced squamous non-small cell lung cancer who received tislelizumab combined with chemotherapy in a previous trial. Researchers want to see how long patients lived and find out who benefits most from this treatment. The goal is to better understand the long-term effects of immunotherapy in this type of lung cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tislelizumab (an immunotherapy drug) combined with chemotherapy
What this could lead to: If successful, this could help doctors identify which patients with advanced squamous NSCLC are most likely to benefit from long-term immunotherapy treatment.
What could go wrong: This is a retrospective analysis of a previous trial, not a new treatment test. Results may not apply to all patients, and long-term data may still be limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SQUAMOUS NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma non-small cell squamous lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)

Contacts and locations

Locations

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.